Aerovate Therapeutics Q2 2025 Earnings Report

Aerovate Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.25
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aerovate Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aerovate Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/11/2025
• Time: N/A
• Conference Call Date: Monday, August 11, 2025
• Conference Call Time: 5:00PM ET

Aerovate Therapeutics (NASDAQ:AVTE) is a clinical‐stage biopharmaceutical company dedicated to developing inhaled therapies for serious respiratory diseases. The company leverages a proprietary aerosol delivery platform designed to optimize drug deposition in the lungs, enabling targeted treatment for conditions such as non–cystic fibrosis bronchiectasis, severe asthma and chronic obstructive pulmonary disease. Aerovate’s development pipeline includes multiple product candidates in various stages of clinical and preclinical research, all focused on improving therapeutic outcomes while minimizing systemic side effects commonly associated with oral or intravenous administration.

Founded in 2018 as a spin‐out from leading academic research programs in pulmonary medicine, Aerovate is headquartered in Boston, Massachusetts, with additional research facilities in the San Francisco Bay Area. The company has established strategic collaborations with academic institutions and contract research organizations across North America and Europe to advance its inhaled drug delivery technology. Aerovate’s R&D efforts center on harnessing novel small molecules and biologics, reformulated for inhalation, to treat both infectious and inflammatory lung conditions.

Aerovate’s leadership team is comprised of industry veterans with deep expertise in respiratory drug development and inhalation device engineering. Chief Executive Officer Dr. Jane Carter brings over 25 years of experience in biotech leadership, having previously held senior roles at global pharmaceutical companies. The company’s board includes experts in pulmonology, drug delivery science and regulatory affairs, guiding Aerovate through late‐stage clinical trials and toward commercialization.